

Supplementary Table 1 Baseline, treatment, and prognostic information for patients in the peptide receptor radionuclide therapy group and control group

Gro up	N o.	Age at liver trans plant ation (year)	G en de r	Pri ma ry mo r t e	K i- 6 7 (%))	SS TR exp ress ion	Pre-t rans plant liver tumo r volu me perce ntage (%)	Tu mor rec urr enc e tim e afte r LT (mo nth)	Recurr ent site	Com bina tion long -acti ng octre otid e	Ti me fro m LT PR RT ini tiat ion (m ont h)	PRRT with ¹⁷⁷ Lu- DOTA TATE cycles	PRRT with ¹⁷⁷ Lu- DOTA TATE cumul ative dose (mCi)	Myelo suppr ession (grade)	Prot ein uria (gra de)	Fol low -up tim e (m ont h)	Ti me of pr og res (m ont h)	Ti m e of de ath (m ont h)	Tre atm ent effi cac y
PRR	C	30	M	Pa	1	+	70	7	Lymp	+	42	2	327	III	II	67	-	67	SD

[illegible]

		as		ale	ncr	0				h					
		e			eas					nodes,					
		1								bone					
Cont	C	73	Fe	Re	3	+	90	3	Lymp	+		38	29	-	PD
rol	as		m	ctu					h						
grou	e		ale	m					nodes,						
p	2								bone,						
									intracr						
									anial						
	C	57	M	Re	2	+	85	12	Lymp	+		19	11	19	PD
	as		ale	ctu	0				h						
	e			m					nodes,						
	3								bone						
	C	61	M	Pa	2	+	80	3	Lymp	+		6	3	6	PD
	as		ale	ncr	0				h						
	e			eas					nodes,						
	4								bone						

C	52	Fe	Re	1	+	85	12	Lymp	+		15	12	-	PD
as		m	ctu	0				h						
e		ale	m					nodes,						
5								bone						
C	61	Fe	Lu	3	+	75	6	Lymp	+		19	12	-	PD
as		m	ng	0				h						
e		ale						nodes,						
6								bone						
C	56	M	Pa	1	+	85	3	Lymp	+		21	-	-	SD
as		ale	ncr	0				h						
e			eas					nodes,						
7								bone						
C	38	M	Pa	1	+	80	12	Bone	+		15	-	-	SD
as		ale	ncr	0										
e			eas											
8														

GBq, gigabecquerel (1 mCi=0.037 GBq). Adverse events were graded according to Common Terminology Criteria for Adverse

Events version 5.0. "None" indicates no proteinuria detected. LT, liver transplantation; SSSTR, somatostatin receptor; PRRT, peptide receptor radionuclide therapy; SD, stable disease; PR, partial response; PD, progressive disease; +, yes; -, no.